A case of acquired haemophilia A in a 70‐year‐old post COVID‐19 vaccine.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      COVID-19 vaccines; HEMOPHILIA; BLOOD coagulation factor VIII antibodies; PROGNOSIS; INTERFERON alpha
    • Abstract:
      CASE This is a 70-year-old male patient with a past medical history of polymyalgia rheumatica and hepatitis C virus with spontaneous clearance, who presented with extensive right upper extremity bruising 8 days after receiving the first dose of the mRNA-1273 SARS-CoV-2 vaccine. In an effort to fight the ongoing SARS-CoV-2 pandemic, the mRNA-1273 SARS-CoV-2 vaccine manufactured by Moderna has been granted Emergency Use Authorization, because of its high efficacy and safety profile.1 We report the first documented case of AHA after receiving the mRNA-1273 SARS-CoV-2 vaccine. We hypothesized that this patient's pre-existing autoimmune condition (polymyalgia rheumatica) increased his risk for the development of FVIII autoantibodies, which could have been triggered by mRNA-1273 SARS-CoV-2 induced immune stimulation. [Extracted from the article]